clinical trial results

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.

Revolution Medicines published Phase 1/2 daraxonrasib data in NEJM, demonstrating promising activity in RAS mutant pancreatic cancer and supporting Phase 3 trial initiation.

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements regarding reproxalap clinical trial results. Investors from Nov 2023-Mar 2026 may be eligible.

Rosen Law Firm sues $ALDX over allegedly false reproxalap trial claims. Investors eligible for compensation; lead plaintiff deadline May 29, 2026.

Aldeyra Therapeutics faces federal securities lawsuit alleging inadequate disclosure of failed clinical trial results for reproxalap. Stock crashed 71% after FDA rejection; investor deadline May 29, 2026.

Rosen Law Firm urges $ALDX investors to act before May 29, 2026 deadline in securities class action alleging false reproxalap trial disclosures.

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.

Class action lawsuit filed against $ALDYA alleging false statements about reproxalap clinical trial results. Claims inconsistent data, unreliable findings.

AtaiBeckley reports Phase 2a results for EMP-01 oral R-MDMA in social anxiety disorder, showing 49% responder rates and 38% symptom reduction versus 15% on placebo.

Rosen Law Firm files securities class action against biopharmaceutical company Aldeyra Therapeutics, alleging false statements. Lead plaintiff deadline: May 29, 2026.

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.

Agios Pharmaceuticals plunged 23% after Novo Nordisk's superior sickle cell drug trial results overshadowed Agios' failed mitapavit candidate, threatening its commercial viability.

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements about reproxalap clinical trial results, covering investors from November 2023 through March 2026.

Large-cap stocks rallied sharply April 13-17, with IonQ (+62.86%), Oklo (+33.35%), and Robinhood (+33.22%) leading gains driven by DARPA contracts, nuclear momentum, and crypto strength.

Class action lawsuit filed against Aldeyra Therapeutics for allegedly false statements on reproxalap trial results, covering investors from November 2023 to March 2026.

Grace Therapeutics reports STRIVE-ON Phase 3 trial success for GTx-104, reducing hypotension and improving outcomes in aneurysmal subarachnoid hemorrhage patients versus oral nimodipine.

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.

Rosen Law Firm filed class action lawsuit against $ALDX alleging false statements. Investors with $100K+ losses urged to join before deadline.

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350, representing 6.76% of holdings. Sale aligns with historical patterns amid company's positive momentum.